Opin vísindi

Germline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndrome

Skoða venjulega færslu

dc.contributor Landspitali - The National University Hospital of Iceland
dc.contributor.author TUDP Study Group
dc.contributor.author Broad Center for Mendelian Genomics
dc.date.accessioned 2023-03-29T01:04:45Z
dc.date.available 2023-03-29T01:04:45Z
dc.date.issued 2022-04-01
dc.identifier.citation TUDP Study Group & Broad Center for Mendelian Genomics 2022 , ' Germline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndrome ' , American Journal of Human Genetics , vol. 109 , no. 4 , pp. 601-617 . https://doi.org/10.1016/j.ajhg.2022.03.002
dc.identifier.issn 0002-9297
dc.identifier.other 56720428
dc.identifier.other de8a2159-1661-44de-bd54-a0566a5aaa4f
dc.identifier.other 85127470624
dc.identifier.other 35395208
dc.identifier.other unpaywall: 10.1016/j.ajhg.2022.03.002
dc.identifier.uri https://hdl.handle.net/20.500.11815/4105
dc.description Funding Information: I.E.S. has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia, Rogcon, Chiesi, Encoded Therapeutics, Xenon Pharmaceuticals, and Knopp Biosciences; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin and Eisai; has served as an investigator for Zogenix, Zynerba, Ultragenyx, GW Pharma, UCB, Eisai, Anavex Life Sciences, Ovid Therapeutics, Epygenyx, Encoded Therapeutics and Marinus; and has consulted for Zynerba Pharmaceuticals, Atheneum Partners, Ovid Therapeutics, Care Beyond Diagnosis, Epilepsy Consortium and UCB. She may accrue future revenue on pending patent WO2009/086591; her patent for SCN1A testing is held by Bionomics and is licensed to various diagnostic companies; and she has a patent for a molecular diagnostic/therapeutic target for benign familial infantile epilepsy (BFIE) (PRRT2), WO/2013/059884. She receives and/or has received research support from the National Health and Medical Research Council of Australia, Medical Research Future Fund, Health Research Council of New Zealand, CURE, Australian Epilepsy Research Fund, and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health. J.P. is co-chief scientific officer for Global Gene Corp. All other authors declare no competing interests. Funding Information: The authors thank the affected individuals and all family members for participating in this research. Please see the supplemental information for a complete list of Acknowledgments and funding. I.E.S. has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia, Rogcon, Chiesi, Encoded Therapeutics, Xenon Pharmaceuticals, and Knopp Biosciences; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin and Eisai; has served as an investigator for Zogenix, Zynerba, Ultragenyx, GW Pharma, UCB, Eisai, Anavex Life Sciences, Ovid Therapeutics, Epygenyx, Encoded Therapeutics and Marinus; and has consulted for Zynerba Pharmaceuticals, Atheneum Partners, Ovid Therapeutics, Care Beyond Diagnosis, Epilepsy Consortium and UCB. She may accrue future revenue on pending patent WO2009/086591; her patent for SCN1A testing is held by Bionomics and is licensed to various diagnostic companies; and she has a patent for a molecular diagnostic/therapeutic target for benign familial infantile epilepsy (BFIE) (PRRT2), WO/2013/059884. She receives and/or has received research support from the National Health and Medical Research Council of Australia, Medical Research Future Fund, Health Research Council of New Zealand, CURE, Australian Epilepsy Research Fund, and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health. J.P. is co-chief scientific officer for Global Gene Corp. All other authors declare no competing interests. Publisher Copyright: © 2022 American Society of Human Genetics Copyright © 2022 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.
dc.description.abstract Neurodevelopmental disorders are highly heterogenous conditions resulting from abnormalities of brain architecture and/or function. FBXW7 (F-box and WD-repeat-domain-containing 7), a recognized developmental regulator and tumor suppressor, has been shown to regulate cell-cycle progression and cell growth and survival by targeting substrates including CYCLIN E1/2 and NOTCH for degradation via the ubiquitin proteasome system. We used a genotype-first approach and global data-sharing platforms to identify 35 individuals harboring de novo and inherited FBXW7 germline monoallelic chromosomal deletions and nonsense, frameshift, splice-site, and missense variants associated with a neurodevelopmental syndrome. The FBXW7 neurodevelopmental syndrome is distinguished by global developmental delay, borderline to severe intellectual disability, hypotonia, and gastrointestinal issues. Brain imaging detailed variable underlying structural abnormalities affecting the cerebellum, corpus collosum, and white matter. A crystal-structure model of FBXW7 predicted that missense variants were clustered at the substrate-binding surface of the WD40 domain and that these might reduce FBXW7 substrate binding affinity. Expression of recombinant FBXW7 missense variants in cultured cells demonstrated impaired CYCLIN E1 and CYCLIN E2 turnover. Pan-neuronal knockdown of the Drosophila ortholog, archipelago, impaired learning and neuronal function. Collectively, the data presented herein provide compelling evidence of an F-Box protein-related, phenotypically variable neurodevelopmental disorder associated with monoallelic variants in FBXW7.
dc.format.extent 17
dc.format.extent 2172218
dc.format.extent 601-617
dc.language.iso en
dc.relation.ispartofseries American Journal of Human Genetics; 109(4)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Lífefna- og sameindalíffræði
dc.subject brain malformation
dc.subject epilepsy
dc.subject F-box protein
dc.subject FBXW7
dc.subject gastrointestinal issues
dc.subject global developmental delay
dc.subject hypotonia
dc.subject intellectual disability
dc.subject macrocephaly
dc.subject Neurodevelopment
dc.subject Proteasome Endopeptidase Complex/metabolism
dc.subject Humans
dc.subject Germ Cells
dc.subject Ubiquitination
dc.subject Germ-Line Mutation
dc.subject F-Box-WD Repeat-Containing Protein 7/chemistry
dc.subject Ubiquitin-Protein Ligases/genetics
dc.subject Neurodevelopmental Disorders/genetics
dc.subject Genetics (clinical)
dc.subject Genetics
dc.title Germline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndrome
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi 10.1016/j.ajhg.2022.03.002
dc.relation.url http://www.scopus.com/inward/record.url?scp=85127470624&partnerID=8YFLogxK
dc.contributor.department Faculty of Medicine
dc.contributor.department Clinical Laboratory Services, Diagnostics and Blood Bank


Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:

Skoða venjulega færslu